Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I/II First-in-Human Study of TT-4 as a Single Agent in Participants With Advanced Selected Solid Tumors

Next Previous
X
Search
Trial Profile

Phase I/II First-in-Human Study of TT-4 as a Single Agent in Participants With Advanced Selected Solid Tumors

Status: Not yet recruiting
Phase of Trial: Phase I/II

Latest Information Update: 05 Apr 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Antineoplastics (Primary) ; PORT-7 (Primary)
  • Indications Carcinoma; Colorectal cancer; Gastric cancer; Liver cancer; Pancreatic cancer; Solid tumours
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors Tarus Therapeutics

    • Most Recent Events

    • 05 Apr 2024 According to ClinicalTrials.gov, the recruitment status of this study is unknown because the information has not been verified recently (last verified May2022).
    • 26 Apr 2022 Planned initiation date changed from 15 Sep 2021 to 15 Dec 2022.
    • 29 Jul 2021 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top